Phase 3 Randomized, Double-Blinded, Placebo-Controlled Multicenter Trial with Open-Label Extension to Evaluate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogren’s Disease
Overview
The ARGENX UNITY study and its extension will test the efficacy and safety of the pharmaceutical Efgartigimod in patients with Sjögren’s disease.
Key Facts
Status: Active/Upcoming
Dates: February 2026 – Present
Principal Investigator: Thomas Grader-Beck, MD
Location: our branch of the study will be conducted at various Johns Hopkins Medicine locations in Baltimore, MD
